Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
A Single Armed Phase ⅡStudy of Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
Sponsor: Henan Cancer Hospital
A PHASE2 clinical study on Lung Adenocarcinoma, this trial is ongoing. The trial is conducted by Henan Cancer Hospital and has accumulated 9 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jul 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
May 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jun 2018 — May 2020 [monthly]
Unknown Status PHASE2
-
May 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2017 — May 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Henan Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .